FocalTherics (NASDAQ:FOCL) Short Interest Up 69.0% in May

FocalTherics (NASDAQ:FOCL) was the target of a large growth in short interest in May. As of May 15th, there was short interest totaling 57,027 shares, a growth of 69.0% from the April 30th total of 33,750 shares. Based on an average daily volume of 48,517 shares, the days-to-cover ratio is currently 1.2 days. Currently, 0.2% of the company’s shares are sold short.

FocalTherics Price Performance

NASDAQ FOCL opened at $4.58 on Thursday. FocalTherics has a 12 month low of $1.21 and a 12 month high of $5.05. The company has a debt-to-equity ratio of 1.79, a current ratio of 1.34 and a quick ratio of 0.99.

FocalTherics (NASDAQ:FOCL) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.02). The company had revenue of $20.48 million for the quarter, compared to the consensus estimate of $19.46 million. FocalTherics had a negative net margin of 41.47% and a negative return on equity of 137.61%. As a group, sell-side analysts expect that FocalTherics will post -0.82 earnings per share for the current year.

Insider Buying and Selling

In other FocalTherics news, Director Joshua Levine bought 10,000 shares of FocalTherics stock in a transaction dated Monday, May 11th. The shares were purchased at an average cost of $4.22 per share, with a total value of $42,200.00. Following the transaction, the director directly owned 35,000 shares of the company’s stock, valued at $147,700. This represents a 40.00% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 10.10% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of FOCL. Flax Pond Capital LLC purchased a new position in shares of FocalTherics in the fourth quarter valued at $2,623,000. Leonteq Securities AG purchased a new position in shares of FocalTherics in the fourth quarter valued at $313,000. Rock Springs Capital Management LP grew its holdings in shares of FocalTherics by 7.1% in the first quarter. Rock Springs Capital Management LP now owns 1,378,000 shares of the company’s stock valued at $5,126,000 after purchasing an additional 91,500 shares in the last quarter. Kovack Advisors Inc. purchased a new position in FocalTherics during the fourth quarter worth $53,000. Finally, Lido Advisors LLC purchased a new position in FocalTherics during the first quarter worth $40,000. 62.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on FOCL. Wall Street Zen downgraded shares of FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of FocalTherics in a report on Tuesday. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $6.00.

FocalTherics Company Profile

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.